Precision Trading with Align Technology Inc. (ALGN) Risk Zones
This article analyzes Align Technology Inc. (ALGN), highlighting a neutral near-term sentiment that could moderate mid-term weakness, with resistance being tested. It details an exceptional 57.7:1 risk-reward short setup and outlines three AI-generated trading strategies: Position Trading, Momentum Breakout, and Risk Hedging, along with multi-timeframe signal analysis. The report also provides key support and resistance levels for different time horizons.
Is Align Technology (ALGN) Stock Outpacing Its Medical Peers This Year?
Align Technology (ALGN) has shown strong performance this year, with its stock up 4.4% year-to-date, significantly outperforming the Medical sector's average return of -5.9%. The company holds a Zacks Rank #2 (Buy), reflecting positive analyst sentiment and an improving earnings outlook. Another outperforming medical stock mentioned is Carlsmed, Inc. (CARL), which is up 2.4% year-to-date.
Align Technology Inc. stock (US0162551016): earnings focus as investors eye next Invisalign growth phase
Align Technology Inc. is under investor scrutiny as its next earnings report approaches, with focus on how the company manages growth and margin pressure amidst increasing competition in the clear aligner market. The company's core business revolves around Invisalign clear aligners and its iTero intraoral scanners, serving orthodontists and general dentists. Investors are watching for signs of growth reacceleration and the expansion of its digital ecosystem beyond orthodontic uses, while also considering risks tied to consumer spending, innovation cycles, and global competition.
Align Tech Shareholders Reaffirm Board and Governance Structure
Align Technology (ALGN) shareholders have re-elected all ten director nominees for one-year terms at their 2026 Annual Meeting, demonstrating strong support for the current leadership and governance structure. They also approved executive compensation, ratified PricewaterhouseCoopers LLP as the independent auditor, and endorsed the special meeting provision in the amended bylaws. Analysts maintain a "Buy" rating on ALGN with a $210 price target, while TipRanks' AI Analyst, Spark, rates it as "Outperform" due to strong financials, despite concerns about valuation and technical momentum.
Align Technology Hosts 400 Doctors at 2026 Invisalign® EMEA Ortho Summit Featuring Digital Orthodontic Solutions Focused on Clinical Indications and Upcoming Align Innovations
Align Technology's 2026 Invisalign® EMEA Ortho Summit in Barcelona gathered 400 orthodontists to explore digital orthodontic solutions and upcoming innovations like the Invisalign Specifix™ Attachment System and integrated buttons. The summit emphasized the integration of digital tools for complex clinical indications, improved treatment precision, and enhanced patient experience. Attendees gained early access to new technologies and participated in peer-led education on optimizing digital workflows.
Align Technology, Inc.: Align Technology Hosts 400 Doctors at 2026 Invisalign EMEA Ortho Summit Featuring Digital Orthodontic Solutions Focused on Clinical Indications and Upcoming Align Innovations
Align Technology recently hosted its 2026 Invisalign EMEA Ortho Summit, bringing together 400 orthodontists to discuss digital orthodontic solutions. The summit showcased innovations like the Invisalign Specifix Attachment System, integrated buttons, and an Invisalign Palatal Expander with integrated hook features. These advancements aim to enhance treatment precision, practice efficiency, and patient experience across various clinical indications.
Align Technology Announces Upcoming Investor Conferences
Align Technology, Inc. ("Align") announced it is scheduled to present at several upcoming financial conferences in late May and early June 2026. The company's executives, including CEO Joseph Hogan and EVP John Morici, will speak at events such as the Stifel 2026 Jaws & Paws Conference, William Blair 46th Annual Growth Stock Conference, 2026 Jefferies Global Healthcare Conference, and Goldman Sachs 47th Annual Global Healthcare Conference. Detailed schedules and webcast information are available on Align Technology's investor relations website.
Will Slowing Growth And Margin Pressure From Competition Change Align Technology's (ALGN) Narrative
Align Technology (ALGN) is facing challenges with slowing revenue growth and margin pressure due to increased competition, as highlighted by only 2.3% annual revenue growth and reduced operating margins. While the company's investment narrative projects substantial revenue and earnings growth by 2029, competitive pressures and discounting may hinder its ability to achieve these targets. The article suggests investors consider these factors and explore different analyst forecasts, which vary widely on the company's future performance.
Will Slowing Growth And Margin Pressure From Competition Change Align Technology's (ALGN) Narrative
Align Technology is facing challenges with slowing revenue growth and margin pressure due to increased competition and macro factors, impacting its profitability and returns on capital. Despite its clinical leadership, the company's annual revenue growth was only 2.3% over the past two years, leading to a revised investment narrative that emphasizes product innovation and cost control. Align's 2026 outlook projects modest revenue growth of 3-4% and an 18.0% GAAP operating margin, with analysts offering differing views on its future performance and fair value.
Align Technology Inc. stock (US0162551016): earnings momentum meets volatile sentiment
Align Technology Inc., known for its Invisalign clear aligners, has shown volatile stock performance despite consistently beating earnings expectations. The company's future performance will depend on its ability to innovate, expand internationally, and balance growth with profitability amidst a competitive dental market. Investors focus on its margins, demand trends, and upcoming guidance as it continues to expand its digital dentistry ecosystem.
Align Technology reports results of annual stockholder meeting
Align Technology (NASDAQ:ALGN) held its 2026 Annual Meeting of Stockholders, where all ten director nominees were elected. Stockholders also approved executive compensation, ratified PricewaterhouseCoopers LLP as the independent accounting firm, and approved a special meeting provision in the company's bylaws. The company's stock is currently trading below its InvestingPro Fair Value, and management has been actively buying back shares, signaling confidence, while Align Technology recently surpassed first-quarter 2026 earnings and revenue expectations.
Align Technology reports results of annual stockholder meeting
Align Technology (NASDAQ:ALGN) held its 2026 Annual Meeting of Stockholders where all ten director nominees were elected. Stockholders also approved executive compensation, ratified PricewaterhouseCoopers LLP as the independent registered public accounting firm, and approved the special meeting provision in the company’s Amended and Restated Bylaws. These votes follow a strong first-quarter 2026 earning report and a reiterated Buy rating from Stifel.
Align Tech Shareholders Reaffirm Board and Governance Structure
Align Technology shareholders have re-elected ten directors to one-year terms, demonstrating broad support for the company's leadership and governance structure. Investors also approved executive compensation, ratified the independent auditor, and endorsed special meeting provisions. TipRanks' AI Analyst, Spark, rates ALGN as "Outperform" due to strong financial quality and a positive earnings outlook, despite a premium valuation and some market concerns.
Shareholders back Align Technology (NASDAQ: ALGN) board, pay and auditor
Align Technology (ALGN) shareholders approved all ten director nominees, executive compensation, and the reappointment of PricewaterhouseCoopers LLP as the independent registered public accounting firm for 2026 at their annual meeting. They also ratified a special meeting provision in the company's Amended and Restated Bylaws. The voting results indicate significant shareholder support for the company's current governance and compensation practices.
Align Technology to Speak at Upcoming Financial Conferences
Align Technology (Nasdaq: ALGN) announced that it is scheduled to speak at four upcoming financial conferences in May and June 2026. The presentations will be webcast live via the Investor Relations section of their website, with an archived replay available for approximately one month. Executives including John Morici, Shirley Stacy, and Joseph Hogan will represent the company at these events.
Biotech Corvus heads to Jefferies and Goldman Sachs health conferences
Corvus Pharmaceuticals (NASDAQ: CRVS) announced it will present a corporate overview and host one-on-one investor meetings at the 2026 Jefferies Global Healthcare Conference on June 3rd and the Goldman Sachs 47th Annual Global Healthcare Conference on June 8th. Webcasts of both presentations will be available live and for 90 days on the company's investor relations website. This follows a period of active investor outreach and clinical advancement for Corvus.
Reasons to Add Align Technology Stock to Your Portfolio Now
Align Technology (ALGN) is positioned for growth due to its expanding Invisalign business and iTero intraoral scanning technology. While the company exhibits strong financial stability with no debt and significant cash reserves, it faces challenges from decreasing average selling prices (ASPs). The article suggests ALGN is a strong buy, highlighting its positive earnings surprise history and growth projections despite recent stock performance.
Align Technology Inc. stock outperforms competitors on strong trading day
Align Technology Inc. (ALGN) saw its stock price advance by 5.30% to $163.38 on Wednesday, outperforming the overall market. This positive performance occurred during a strong trading session where both the S&P 500 Index and the Dow Jones Industrial Average also registered gains. Despite the rise, the company's stock closed 21.57% below its 52-week high.
Is This the Right Time to Retain ILMN Stock in Your Portfolio?
Illumina Inc. (ILMN) is demonstrating strong progress with its long-term strategy, driven by growth in its core sequencing business, multiomics expansion, and software capabilities, with clinical demand being a key driver. Despite this positive momentum and a significant stock surge, the company faces headwinds from operations in China and broader macroeconomic pressures. Efforts to transition to NovaSeq X and focus on core genomics are promising, but challenges in the Chinese market and inflationary costs remain concerns.
Align Technology to Speak at Upcoming Financial Conferences
Align Technology (Nasdaq: ALGN) announced its participation in four upcoming financial conferences in May and June 2026. Company executives, including CFO John Morici and CEO Joseph Hogan, are scheduled to present at events such as the Stifel 2026 Jaws & Paws Conference, William Blair 46th Annual Growth Stock Conference, Jefferies Global Healthcare Conference, and Goldman Sachs 47th Annual Global Healthcare Conference. Webcasts of these presentations will be available via the Investor Relations section of Align Technology's website.
High Cash Flow Stocks with Weak Returns: Illinois Tool Works, Align Technology, GE HealthCare - News and Statistics
An analysis by StockStory highlights that strong cash flow does not always equate to strong investment returns, citing companies like Illinois Tool Works, Align Technology, and GE HealthCare as examples. These companies, despite generating substantial cash, face challenges such as sluggish revenue growth, declining operating margins, or difficulties in organic expansion. The article details specific financial and operational issues for each company, suggesting that other factors beyond cash flow heavily influence their market performance.
Align Technology Inc. stock (US0162551016): clear aligner specialist in focus after recent share price swing
Align Technology Inc. is under investor scrutiny due to volatile trading and challenging dental demand, following its Q1 2025 results. The company, a leader in clear aligner systems and digital dentistry, reported revenue growth but noted macroeconomic conditions affecting patient volumes. The stock's performance is influenced by its core Invisalign product, iTero scanners, and sensitivity to economic cycles and competition in the expanding clear aligner market.
Align Technology Inc. stock underperforms Tuesday when compared to competitors
Align Technology Inc. (ALGN) stock declined by 2.28% on Tuesday, closing at $155.16, in a generally negative trading session where the S&P 500 and Dow Jones Industrial Average also fell. The company's stock is currently 25.51% below its 52-week high of $208.31, achieved on July 29th.
Is This the Right Time to Hold DGX Stock in Your Portfolio?
Quest Diagnostics (DGX) is showing strong growth potential, particularly in its Diagnostic Information Services (DIS) segment and Advanced Diagnostics. The company's strategic initiatives, including enterprise-wide AI adoption and its Invigorate program, are expected to drive operational improvements and continued financial performance. While facing challenges such as escalating debt levels and macroeconomic volatility, the stock continues to receive a "Buy" rating from Zacks.
Is This the Right Time to Hold DGX Stock in Your Portfolio?
Quest Diagnostics (DGX) is showing strong growth potential, particularly in its Diagnostic Information Services and Advanced Diagnostics segments, with an earnings yield of 5.73%. Despite concerns about escalating debt and macroeconomic volatility, the company's operational excellence initiatives and strategic partnerships are poised to drive future performance. Analysts also predict significant earnings per share and revenue growth for 2026, making it a "Buy" rated stock according to Zacks.
We Like Align Technology's (NASDAQ:ALGN) Earnings For More Than Just Statutory Profit
Align Technology's recent earnings report showed no surprises in share price movement, despite unusual items reducing statutory profit by US$154m. Our analysis suggests that these one-off costs might mask the company's true earning potential, implying that future profits could be higher in their absence. Additionally, the company has demonstrated strong earnings per share growth of 47% annually over the last three years.
Align Technology Inc stock (US01741R1023): strong Q1 2026 earnings keep clear aligner growth story in focus
Align Technology Inc. (ALGN) reported better-than-expected Q1 2026 earnings with EPS of $2.58 and revenue of $1.04 billion, driven by strong performance in its clear aligner business. Despite the positive results, the stock has experienced recent volatility, highlighting a disconnect between operational strength and market sentiment. The article discusses Align Technology's core business model, key revenue drivers, competitive landscape in the digital orthodontics market, and risks including competitive pressure, macroeconomic trends, and regulatory developments, emphasizing its appeal to US investors looking for exposure to healthcare, consumer discretionary, and technology sectors.
Align Technology stock (US0162551016): Short interest rises after recent earnings
Align Technology (US0162551016) is under scrutiny as new data shows a significant increase in short interest, with bearish bets rising by 11.71% as of April 30, 2026. This indicates a more cautious market sentiment despite the company recently beating its Q1 earnings per share consensus. The dental device maker, known for its Invisalign clear aligners, continues to be a closely watched stock at the intersection of healthcare, consumer demand, and digital dentistry.
Align Technology Inc. stock (US0162551016): Rising short interest adds a new angle for investors
Align Technology Inc., known for its Invisalign clear aligners, is experiencing a notable increase in short interest, with 4.26 million shares sold short as of April 30, 2026, representing an 11.71% rise. This growing bearish sentiment contrasts with a generally positive analyst consensus and recent solid earnings performance, including double-digit EPS outperformance. The article explores Align's core business model, key revenue drivers, and the implications of this divergence in market sentiment for investors.
We Like Align Technology's (NASDAQ:ALGN) Earnings For More Than Just Statutory Profit
Align Technology's recent earnings report, while showing no surprises in share price, indicates potentially positive underlying factors. The company's statutory profit was reduced by US$154m due to unusual items, which are unlikely to recur, suggesting future profitability could be higher. This observation implies that Align Technology's statutory profit may be understating its true earnings potential, especially given its impressive 47% annual EPS growth over the last three years.
We Like Align Technology's (NASDAQ:ALGN) Earnings For More Than Just Statutory Profit
Align Technology's recent earnings report, despite shares remaining unchanged, contains positive underlying factors. The statutory profit was reduced by US$154m due to unusual items, which are generally not repeated and indicate a potentially higher profit next year. This suggests that Align Technology's reported profit may be understating its true earnings potential, especially given its 47% annual EPS growth over the last three years.
Setback for Align and Carpmaels & Ransford in orthodontic aligners dispute
Align Technology experienced a setback when the Düsseldorf local division dismissed its application for provisional measures against Angelalign, allowing Angelalign to continue marketing its orthodontic aligners. The court ruled that Align failed to sufficiently establish infringement of its EP 4 295 806 patent. This decision contrasts with a previous preliminary injunction granted to Align earlier in the year regarding a different patent related to orthodontic treatment planning software.
Stifel reiterates Buy rating on Align Technology stock at $210
Stifel has reiterated its Buy rating on Align Technology Inc. (NASDAQ:ALGN) with a price target of $210.00, indicating significant upside despite the stock's recent decline. The firm updated its financial model based on new clear aligner data and reviewed the company's 10-Q filing. Align Technology recently exceeded Q1 2026 earnings and revenue expectations, demonstrating continued growth.
Northwestern Mutual Wealth Management Co. Purchases 544,072 Shares of Align Technology, Inc. $ALGN
Northwestern Mutual Wealth Management Co. significantly increased its stake in Align Technology (NASDAQ:ALGN) during Q4, acquiring 544,072 additional shares to hold a total of 545,604 shares valued at $85.2 million. This comes as Align Technology reported strong quarterly results, exceeding EPS and revenue expectations, and announced a $200 million share buyback program. Analysts generally maintain a "Moderate Buy" rating for the company with an average price target of $205.85.
Align Technology Inc. stock (US0162551016): Short interest rises as investors reassess growth story
Short interest in Align Technology Inc. spiked by 11.71% as of April 30, 2026, indicating increased skepticism among investors regarding the company's growth story amidst shifting demand and margin pressures. Despite this, Align Technology, known for its Invisalign system and iTero scanners, maintains a strong market position and benefits from long-term orthodontic demand. The rise in short bets suggests that some market participants are positioning for potential downside or volatility, questioning valuation or competitive dynamics.
LENSAR stock (US52633C1071): eye-surgery specialist back in focus after Alcon deal collapse
LENSAR (LNSR) stock is back in focus after Alcon terminated its planned acquisition in March 2026, raising questions about LENSAR's standalone strategy and growth prospects. The company, which specializes in femtosecond laser systems for cataract and refractive eye surgery, now faces reliance on its core business model and competition from larger device groups. Its future performance will depend on expanding its installed base, driving recurring revenues, and navigating the market without a potential acquirer.
Align Technology stock (US01741R1023): investors eye Q1 2026 recovery and Invisalign demand
Align Technology's Q1 2026 results show improving demand for Invisalign and iTero scanners, though the stock remains below previous highs. The company's core business involves clear aligner systems and digital tools for orthodontics, focusing on B2B sales to dental professionals while also investing in consumer marketing. Future performance hinges on innovation, provider relationships, growth initiatives, and navigating macroeconomic conditions and competition.
SpyGlass Pharma Reports First Quarter 2026 Financial Results and Provides Corporate Updates
SpyGlass Pharma announced its Q1 2026 financial results and provided corporate updates, highlighting progress in its BIM-IOL System and BIM-DRS programs. The company reported successful topline 12-month data from the BIM-IOL System Phase 1/2 trial, showing significant IOP reduction and elimination of topical eye drops for most participants. Following its IPO in February 2026, SpyGlass Pharma is well-funded, with $251.0 million in cash, expected to support operations through 2028.
Align Technology Inc. stock underperforms Friday when compared to competitors
Align Technology Inc. (ALGN) stock fell 2.04% on Friday, closing at $157.25. This underperformance occurred during a generally dismal trading session, with the S&P 500 Index and Dow Jones Industrial Average also declining. This marked the third consecutive day of losses for Align Technology Inc.
Capital International (ALGN) reports 3.9M shares, 5.5% stake
Capital International Investors has filed an amended Schedule 13G/A, revealing beneficial ownership of 3,906,972 shares of Align Technology, Inc. (ALGN) common stock. This stake represents 5.5% of the 71,617,275 shares outstanding. The filing indicates that Capital International Investors holds sole voting power for 3,885,958 shares and sole dispositive power for 3,906,972 shares, with the disclosure signed by a Senior Vice President.
Organogenesis Holdings Inc. - Class A (NQ: ORGO)
This article provides recent news headlines related to Organogenesis Holdings Inc. - Class A (ORGO), though most of the listed articles are from April 2021 and discuss other companies like Repligen, Quanterix, Reviva Pharmaceuticals, Align Technology, Novocure, and various biotech stocks. It also displays the current stock price and performance for Organogenesis Holdings Inc. - Class A.
Align Technology stock (US0162551016): earnings and product demand stay in focus
Align Technology's financial performance is closely tied to the demand for its Invisalign clear aligner system and iTero digital dentistry tools. Investors monitor orthodontic case volumes, product mix, and operating discipline, as the company's success reflects both healthcare utilization and discretionary consumer spending trends in the US and globally. Key challenges include competitive pressures, foreign exchange impacts, and maintaining growth in scanner adoption while ensuring profitability.
CapsoVision (Nasdaq:CV) - Stock Analysis
CapsoVision (Nasdaq:CV) is a medical technology company specializing in endoscopic video imaging devices for gastrointestinal imaging, currently valued at US$322.5m. The company faces significant financial risks, including less than a year of cash runway and continued unprofitability, although revenue is forecast to grow by 27.2% annually. Recent developments include an FDA 510(k) submission for an AI-assisted reading module and a Breakthrough Device Designation application for pancreatic cancer screening.
Sequoia Financial Advisors LLC Has $1.25 Million Stock Position in Align Technology, Inc. $ALGN
Sequoia Financial Advisors LLC significantly increased its stake in Align Technology, Inc. (NASDAQ:ALGN) by 320.1% in the fourth quarter, now holding 7,986 shares valued at approximately $1.25 million. This increase follows Align Technology's strong quarterly results, which exceeded analyst expectations, and the approval of a $200 million share buyback program. Analysts generally maintain a "Moderate Buy" consensus rating for ALGN with an average price target of $205.85.
Is Align Technology (ALGN) Quietly Redefining Its Moat With Fully Digital, 3D‑Printed Orthodontics?
Align Technology is enhancing its digital orthodontics platform through fully digital, 3D-printed solutions, as showcased at the AAO 2026 Annual Session. These innovations, like the Invisalign Specifix Attachment System, aim to shift manual procedures to its integrated platform, potentially mitigating competition and pricing pressures. While some analysts are pessimistic, Align's strategy could strengthen its market position and influence its investment narrative, projecting significant revenue and earnings growth by 2029.
Align Technology Inc. stock underperforms Wednesday when compared to competitors
Align Technology Inc. (ALGN) stock declined by 2.44% on Wednesday, closing at $161.75. This performance occurred during a mixed trading day where the S&P 500 rose, but the Dow Jones Industrial Average fell. The stock is currently 22.35% below its 52-week high of $208.31.
Align Technology stock (US0162551016): Beats Q1 estimates with EPS $2.58, revenue up 6.2%
Align Technology reported stronger-than-expected Q1 results, with EPS of $2.58 against estimates of $2.26 and revenue of $1.04 billion, a 6.2% increase year-over-year. The company's core business revolves around Invisalign clear aligners and iTero scanners, maintaining a dominant market share in the US. This performance highlights operational efficiency and continuous growth in the expanding clear aligner market.
Align Technology stock (US0162551016): Beats Q1 estimates with EPS $2.58, revenue up 6.2%
Align Technology (US0162551016) reported strong Q1 2026 results, exceeding analyst expectations with an EPS of $2.58 against forecasts of $2.26, and revenue reaching $1.04 billion, marking a 6.2% year-over-year increase. The company maintains its leadership in the clear aligner market with its Invisalign system, benefiting from a consumables-driven business model and expansion in North America, EMEA, and APAC. This performance highlights resilient demand and reinforces its dominant position in the orthodontics sector.
Envista Holdings Corporation Common Stock (NY: NVST
This compilation provides recent news and financial updates for Envista Holdings Corporation (NYSE:NVST). It features headlines covering Q1 2026 earnings results, analyst insights, product launches, and broader healthcare industry analysis. The articles highlight Envista's financial performance, market reactions, and related stock movements.
Digital Orthodontic Ecosystems
Digital orthodontic ecosystems are revolutionizing dental care by integrating scanning, treatment planning, manufacturing, and monitoring into cohesive digital platforms. Align Technology recently unveiled new AI-assisted orthodontic tools, including 3D-printed attachment systems and enhanced palatal expanders, aiming to improve workflow precision and patient comfort. These advancements, which also feature enhanced intraoral scanning and automated treatment customization, are driven by a growing demand for AI-assisted workflows that offer efficiency and personalized patient experiences.
